4//SEC Filing
Feder Julie B 4
Accession 0000950170-24-116029
CIK 0001501796other
Filed
Oct 20, 8:00 PM ET
Accepted
Oct 21, 6:23 PM ET
Size
30.5 KB
Accession
0000950170-24-116029
Insider Transaction Report
Form 4
Feder Julie B
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−2,631→ 32,359 totalExercise: $4.25Exp: 2030-03-16→ Common Stock (2,631 underlying) - Exercise/Conversion
Common Stock
2024-10-18$2.74/sh+17,500$47,950→ 151,776 total - Sale
Common Stock
2024-10-18$12.03/sh−25,131$302,361→ 134,276 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−17,500→ 68,257 totalExercise: $2.74Exp: 2028-10-03→ Common Stock (17,500 underlying) - Exercise/Conversion
Common Stock
2024-10-18$4.25/sh+2,631$11,182→ 154,407 total - Exercise/Conversion
Common Stock
2024-10-18$5.48/sh+5,000$27,400→ 159,407 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−5,000→ 120,547 totalExercise: $5.48Exp: 2031-06-28→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested.
- [F4]The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021.
Documents
Issuer
Aura Biosciences, Inc.
CIK 0001501796
Entity typeother
Related Parties
1- filerCIK 0001710237
Filing Metadata
- Form type
- 4
- Filed
- Oct 20, 8:00 PM ET
- Accepted
- Oct 21, 6:23 PM ET
- Size
- 30.5 KB